A cat with myelodysplastic syndrome by administration of the methylation inhibitor Azacytidine |
| |
| Authors: | Masaharu HISASUE Mina TANAKA Sakurako NEO |
| |
| Affiliation: | 1)Laboratory of Small Animal Internal Medicine, Azabu University, 1-17-71 Fuchinobe, Chuo-ku, Sagamihara, Kanagawa 252-5201, Japan;2)Azabu University Veterinary Teaching Hospital, Azabu University, 1-17-71 Fuchinobe, Chuo-ku, Sagamihara, Kanagawa 252-5201, Japan;3)Shoko Animal Hospital, 407-8 Shinzen-cho, Soka, Saitama 340-0054, Japan;4)Laboratory of Clinical Diagnosis, Azabu University, 1-17-71 Fuchinobe, Chuo-ku, Sagamihara, Kanagawa 252-5201, Japan |
| |
| Abstract: | A 5-year-old female cat with nonregenerative anemia and thrombocytopenia was diagnosed with myelodysplastic syndromes (MDS), since peripheral blood and bone marrow (BM) examination revealed various dysplasias and a blast ratio of 19%. Chemotherapy with azacytidine (AZA; 70–35 mg/m2, 3–5 days, three cycles) and treatment with prednisolone, antibiotics, and vitamin K2, and blood transfusion were performed. On day 106, blast cells and dysplasia had decreased in the BM, and the cat remained alive for at least 1,474 days. This report is the first on feline MDS treated with AZA, suggesting appropriate drug dosage, interval and effective combination should be investigated and the pharmacological and cell biological mechanisms needs to be elucidated in the future. |
| |
| Keywords: | cat chemotherapy leukemia myelodysplasia survival duration |
|
|
